Goran Ando is listed as a director on 2 SEC Form D filings by 2 issuers between Aug 2020 and Jan 2021: Cartesian Therapeutics, Inc. (Gaithersburg, MD — biotechnology — 2020; $130M reported sold to 26 investors) and EyePoint Pharmaceuticals, Inc. (Watertown, MA — pharmaceuticals — 2021; $15.7M reported sold to 3 investors).
What this means 2 separate companies raised money with this person listed as director. Across those companies the filings report $145.7M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Goran Ando and found 4 differences: Goran Ando appears on 1 deal that stopped filing before reaching its target; Form D filed 18 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.